Histological Type, n (%) |
|
Ductal invasive |
12 (57.14%) |
13 (59.09%) |
25 (58.14%) |
0.1472 |
Lobular invasive |
3 (14.29%) |
2 (9.09%) |
5 (11.63%) |
Other |
6 (28.57%) |
7 (31.82%) |
13 (30.23%) |
Tumor Size (T), n (%) |
|
T≤ 2 cm |
7 (33.33%) |
9 (40.90%) |
16 (37.21%) |
0.7546 |
T > 2 cm |
14 (66.67%) |
13 (59.10%) |
27 (62.79%) |
Positive lymph nodes, n (%) |
|
0 lymph nodes |
11 (52.38%) |
12 (54.54%) |
23 (53.49%) |
0.8948 |
1–3 lymph nodes |
6 (28.57%) |
5 (22.73%) |
11 (25.58%) |
≥4 lymph nodes |
4 (19.05%) |
5 (22.73%) |
9 (20.93%) |
TNM Stage, n (%) |
|
I |
4 (19.05%) |
4 (18.18%) |
8 (18.61%) |
0.4609 |
II |
13 (61.90%) |
11 (50.00%) |
24 (55.81%) |
III |
4 (19.05%) |
7 (31.82%) |
11 (25.58%) |
Hormone receptor status, n (%) |
|
ER+/PR+ |
10 (47.62%) |
11 (50.00%) |
21 (48.84%) |
0.9571 |
ER−/PR− |
6 (28.57%) |
5 (22.73%) |
11 (25.58%) |
ER+/PR− |
3 (14.28%) |
3 (13.64%) |
6 (13.95%) |
ER−/PR+ |
2 (9.53%) |
3 (13.64%) |
5 (11.63%) |
Histological Grade, n (%) |
|
I |
3 (14.29%) |
2 (9.09%) |
5 (11.63%) |
0.4754 |
II |
5 (23.81%) |
9 (40.91%) |
14 (32.56%) |
III |
13 (61.90%) |
11 (50.00%) |
24 (55.81%) |